• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Gao on study of resistance to PARP inhibitor olaparib in prostate cancer


In this video, Allen C. Gao, MD, PhD, discusses the background and findings of the study, “Resistance to olaparib is dependent on re-emergence from G2/M arrested senescence,” presented at the 2021 American Urological Association Annual Meeting. Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.